Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Active-controlled Non-inferiority Study of the Efficacy and Safety of OX219 for the Induction of Treatment of Opioid Dependence

NCT01848054 is registered in ClinicalTrials.gov with Orexo AB as lead sponsor.

NCT NCT01848054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01848054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Active-controlled Non-inferiority Study of the Efficacy and Safety of OX219 for the Induction of Treatment of Opioid Dependence
Lead sponsor
Orexo AB
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2013
Completion date
January 31, 2014
Enrollment
313 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

opiate dependence, opioid-related disorders